Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

Oxford COVID-vaccine paper highlights lingering unknowns about results

The Oxford–AstraZeneca partnership is the first major developer to publish detailed data from phase III trials.
By
  1. Heidi Ledford

The first formally published results from a large clinical trial of a COVID-19 vaccine — which scientists hope could be among the cheapest and easiest to distribute around the world — suggest that the vaccine is safe and effective. But the data also highlight a number of lingering unknowns, including questions about the most effective dosing regimen and how well it works in older adults.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 588, 378-379 (2020)

doi: https://doi.org/10.1038/d41586-020-03504-w

References

  1. Voysey, M. et al. Lancet https://doi.org/10.1016/S0140-6736(20)32661-1 (2020).

    Article  Google Scholar 

  2. Ramasamy, M. N. et al. Lancet https://doi.org/10.1016/S0140-6736(20)32466-1 (2020).

    Article  Google Scholar 

Download references

Subjects

Latest on:

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links